© AzurPharma Ltd.
Company Number 399192
Dublin, Ireland, January 7th, 2008 - Azur Pharma ("Azur") and IntelGenx Corp. (OTCBB:IGXT) ("IntelGenx") today announced the signing of a License and Development Agreement to develop and commercialize prescription prenatal vitamin products for the U.S. market using IntelGenx's proprietary patented oral drug delivery technology.
Under the agreement, the companies expect to launch two products in the first half of 2008. IntelGenx will complete the development of the products and will be entitled to royalties based on Azur's net revenues from the products. Azur will be responsible for commercialization and marketing activities in the U.S.
Seamus Mulligan, Chairman and Chief Executive of Azur Pharma, said, "We are pleased to enter this agreement with IntelGenx. These important products for pregnant women will be our second and third launches of Women's Health products in the U.S., and will leverage the infrastructure arising from our acquisition of Pharmelle in 2007. We are pleased to be working with IntelGenx and believe their technologies offer significant benefits to our patients."
Horst G. Zerbe, President and Chief Executive of IntelGenx, said, "This agreement marks an important milestone for IntelGenx as it represents the commercialization of the first product using our drug delivery technologies. We are indeed pleased to partner with Azur Pharma, which is noted for its strong U.S. national sales infrastructure."
About Azur Pharma
Azur is a privately held pharmaceutical company dedicated to enhancing patients' lives by developing and marketing pharmaceutical products in specialist therapeutic areas. Azur's strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development and approved pharmaceutical products. (Website: www.azurpharma.com)
About IntelGenx Corp.
IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The company's research and development pipeline includes products for the treatment of osteoarthritis, pain management, hypertension, and smoking cessation. More information is available about the company at www.intelgenx.com and at www.cfsg1.com.
Azur Media Contact
MRPA Kinman Communications
Mr. Ray Gordon,
Telephone: +353-1-7038619/+353-87-2417373
E-mail: ray@mrpakinman.ie